PEITC was also shown to induce ROS generation in p53-deficient chronic lymphocytic leukemia cells (CLL) and therefore could be effective for treatment of CLL patients with p53 mutations [95]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.